Is 506260 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 506260 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 506260 (₹222.95) is trading above our estimate of fair value (₹4.24)
Significantly Below Fair Value: 506260 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 506260?
Key metric: As 506260 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 506260. This is calculated by dividing 506260's market cap by their current
earnings.
What is 506260's PE Ratio?
PE Ratio
18.9x
Earnings
₹590.23m
Market Cap
₹11.17b
506260 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 506260 is good value based on its Price-To-Earnings Ratio (18.9x) compared to the Indian Pharmaceuticals industry average (33.6x).
Price to Earnings Ratio vs Fair Ratio
What is 506260's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
506260 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
18.9x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 506260's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/12/22 03:59
End of Day Share Price
2024/12/20 00:00
Earnings
2024/09/30
Annual Earnings
2024/03/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anuh Pharma Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.